Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

by Jennifer Edelmann, Arran D. Dokal, Emma Vilventhraraja, Karlheinz Holzmann, David Britton, Tetyana Klymenko, Hartmut Döhner, Mark Cragg, Andrejs Braun, Pedro Cutillas, John G. Gribben
Published 2021-02-01